STAGE IV PANCREATIC CANCER AJCC V8

This study tests whether switching from one chemotherapy combination to another before surgery can help people with pancreatic cancer. It includes patients whose tumors can be removed or are borderline removable. The goal is to see if the switch leads to better surgical outcomes …

This study looks at whether adding the immunotherapy drug pembrolizumab to the standard drug olaparib works better than olaparib alone for people with metastatic pancreatic cancer who have inherited BRCA1 or BRCA2 mutations. About 88 participants will be randomly assigned to one …

This study tests a combination of two drugs, palbociclib and binimetinib, in people with cancers that have a RAS mutation, including certain ovarian and pancreatic cancers. The goal is to see if the combination can slow cancer growth better than one drug alone. About 199 adults w…

This study tests a new method called sonoporation, which uses ultrasound and tiny gas bubbles to help chemotherapy drugs get into cancer cells more effectively. About 120 adults with advanced pancreatic cancer will receive either standard chemotherapy alone or chemotherapy plus s…

This early-phase study tests a new drug combination for people with advanced pancreatic cancer that has a specific marker (mesothelin). The treatment pairs a targeted chemotherapy (anetumab ravtansine) with immunotherapy drugs (nivolumab, ipilimumab) and/or standard chemo (gemcit…

This early-phase study tests a combination of two drugs—calaspargase pegol-mknl and cobimetinib—in people with advanced pancreatic cancer that has spread. The goal is to find the safest dose and see if the combo can control the disease by cutting off the cancer cells' food supply…

This early-phase study tests a new drug (M6620) combined with a standard chemotherapy (irinotecan) in adults with advanced solid tumors that have spread or can't be removed by surgery. The main goal is to find the safest dose and check for side effects. About 66 participants with…

This early-stage trial tests a new drug called CA-4948 added to standard chemotherapy for people with pancreatic cancer that has spread or can't be removed. The goal is to find the safest dose and see if the combination can shrink tumors or stop them from growing. About 43 adults…

This study compares a three-drug chemotherapy combination (nab-paclitaxel, gemcitabine, plus cisplatin) against the standard two-drug combination (nab-paclitaxel plus gemcitabine) for people with metastatic pancreatic cancer that has spread to other parts of the body. Only patien…

This early-stage trial aimed to test the safety and effectiveness of STIL101, a personalized cell therapy made from a patient's own tumor-fighting T cells, for several advanced cancers including pancreatic, colorectal, kidney, cervical, and melanoma. The treatment involved collec…

This study compares two chemotherapy regimens in 176 older patients whose pancreatic cancer has spread. One group gets gemcitabine plus nab-paclitaxel; the other gets a combination of 5-FU, leucovorin, and liposomal irinotecan. The goal is to see which treatment helps patients li…

This study tests whether a combination of two drugs, lenvatinib and pembrolizumab, can help control advanced pancreatic cancer that cannot be removed by surgery. About 28 adults whose cancer has not worsened after initial treatment will receive these drugs as maintenance therapy.…

This early-phase trial tests a combination of two drugs—niraparib (a PARP inhibitor) and dostarlimab (an immunotherapy)—in people with BRCA-mutated breast, pancreas, or ovarian cancers that have spread or cannot be surgically removed. The goal is to see if the combo can shrink tu…

This study looks at whether a supervised, at-home resistance training program done via tablet is safe and helpful for people with advanced pancreatic cancer. About 25 participants will do guided exercises while receiving chemotherapy or recovering from surgery. The goal is to see…